Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(2-carbamoylmethyl–5-propyl-octahydro-indol–7‑yl)acetic acid is a synthetic small molecule belonging to the indole carboxylic acids class. It has not been approved for clinical use and is considered an experimental compound. Its primary structure features an indole core with carbamoylmethyl and propyl substitutions, as well as an acetic acid side chain. The compound has been identified in chemical databases but does not have any known approved indications or marketed formulations. According to DrugBank, it has been studied for its interaction with Group IIE secretory phospholipase A2, suggesting a potential mechanism of action related to enzyme inhibition[1][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2-carbamoylmethyl-5-propyl-octahydro-indol-7-yl)acetic acid.